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Accepted 3 November 2009Placenta that is morbidly adherent is considered as an
abnormality in placentation leading to its abnormally firm
attachment to the myometrium because of the absence of
deciduas basalis leading to its incomplete separation at the
time of delivery. One of the potentially catastrophic obstetric
complications, placenta accreta is alarmingly on the rise with
high maternal morbidity and mortality rate being as high as
7% [1]. The untoward complications may include severe
postpartum hemorrhage with its resultant coagulopathy, post-
partum curettage, uterine perforation, shock, infection, loss of
fertility, and even death [2].
A patient aged 33 years reported overshooting her periods
by 10 days and tested positive for pregnancy. Her obstetric
history readsdthird gravida and parity two with one alive
issue. The last time she was pregnant she had retained
placenta following full-term vaginal delivery at home,
complicated by postpartum hemorrhage (Fig. 1). Thereafter,
taken to a private hospital, she underwent three unsuccessful
attempts of manual removal/uterine dilatation and curettages
and five units of blood transfusion interspersed with repeated
episodes of excessive bleeding per vaginally. Failing to
manage by this surgical approach, she was referred for
hysterectomy. Her first gestation period and vaginal delivery
was uneventful.
On admission at Maharishi Markandeshwar Institute of
Medical Sciences and Research after 18 days of parturition,
she was conscious, cooperative having stable general condition
with normal vitals but significant pallor, no cyanosis, and no
abnormality detected in cardiovascular or respiratory system.
On abdominal examination, her uterus was felt enlarged to 20
weeks size, well contracted with pelvic examination showing
moderate amount of bleeding per vaginum, and patulous but
closed os of 20e22 weeks sized uterus.* Corresponding author. House No. 7, Doctors Colony, Opposite ITI,
Ambala City, Haryana, India.
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doi:10.1016/j.tjog.2009.11.001On investigating, her hemoglobin was 7.5 g/dL, blood
group B positive; and rest of the hemogram, urine routine
examination, platelet count, coagulation profile, and liver and
renal function tests were normal. Vaginal swab was sent for
culture sensitivity, which was later reported to be sterile.
Sonography revealed uterus to be of enlarged size with
endometrial cavity showing an echogenic mass of dimensions
8.1 5.8 cm, suggestive of placenta.
On color Doppler, there was absence of a hypoechoic retro-
placental zone, presence of dilated vessels extending from the
placenta through the myometrium, irregular cystic spaces in the
placenta, and pulsatile maternal blood flow within these hypo-
echoic spaces; these findings were highly suggestive of placenta
accreta and confirmed the provisional diagnosis of adherent
placenta earlier diagnosed at the failed attempts at manual
removal.
Supportive measures, such as one unit blood transfusion and
broad-spectrum antibiotics, were initiated. Considering the
hemodynamically stable condition and minimal vaginal
bleeding, she was managed conservatively. The modalities
adopted were the placenta was left in situ and methotrexate
injection was given intramuscularly in the dosage of 1 mg/kg
body weight repeated at 72e96 hourly intervals for three doses
depending on the dimensions and vascularity of the endometrial
mass representing adherent placentawith serial ultrasonography
and color Doppler studies, which showed gradual reduction.
Total and differential leukocyte counts were routinely done and
they remained within normal limits. Size of the uterus decreased
remarkably and was not palpable abdominally after 7 days.
Vaginal bleeding never became alarming and vaginal discharge
never smelt obnoxious.
Patient was discharged satisfactorily after 11 days. On
subsequent three follow-ups, every 5 days, patient remained
afebrile with no evidence or history of infection and near
normal sonological findings after a fortnight. Complete
resorption of placenta was confirmed on ultrasonography
carried out at 12 weeks. Patient started menstruating regularly
after about 4 months.cs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. Retained placenta.
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mentioned previously eventful postnatal period. In her regular
antenatal visits, ultrasonography and color Doppler were
conducted at frequent intervals to rule out any evidence of
recurrent placenta accreta. At term, she had Caesarean section
for fetal indication. The placental separation was normal and
postnatal period was uneventful.
The ever-increasing incidence of this life endangering
condition of placenta accreta is considered between 1 in 7,000
and as high as 1 in 540 pregnancies [3]. The risk factors for
placenta accreta are previous uterine surgery (such as caesarean
sections, myomectomy), previous dilatation and evacuation,
placenta previa, advanced maternal age, multiparity, Asher-
man’s syndrome, and presence of fibroids [2]. It is important to
make an early and accurate diagnosis for appropriate manage-
ment and reduction of associated morbidity, thereof, and
prenatal diagnosis may be established by ultrasound, color
Doppler, and magnetic resonance imaging [4].
Presently, there has been a gradual shift toward its conser-
vative management pioneered by Arulkumaran et al [5]
away from the age-old traditional approach of hysterectomy.
The current trend is of uterine conservation and leaving
the adherent placenta in situ with adjuvant treatment of
methotrexate [6]. The outcome varies widely ranging from
expulsion at 7 days to progressive resorption in roughly 6
months [7].
Mussalli et al [8] in 2000 managed three cases of placenta
accreta with methotrexate and succeeded in preserving the
uterus in two cases. One case of placenta percreta and threecases of partial placenta increta were managed effectively with
methotrexate by Sonin [9] in 2001 and Pinho et al [10] in
2008, respectively.
Another study on conservative management mentions
leaving the placenta accreta in situ with one of these associated
treatments, such as bilateral hypogastric artery ligation and
medical treatment with methotrexate or uterine artery emboli-
zation; placental resorption happened in most cases, although
there was no maternal mortality, but the conservative treatment
failed in 2 of the 13 cases where hysterectomy had to be resorted
to [11]. Moreover, conservative approach in selected cases is
beneficial in preserving fertility [12].
Conservative strategy is the best approach available for
hemodynamically stable patients of placenta accreta especially
in those categories of patients where retention of fertility is
a necessity/desperation.
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